{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:50:36Z","timestamp":1767192636992,"version":"3.45.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.numecd.2025.104233","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:29:18Z","timestamp":1752596958000},"page":"104233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A new role for glucagon: from secondary hormone to key player"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-5991","authenticated-orcid":false,"given":"Michelantonio","family":"De Fano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Malara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Rucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Manco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine G.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geremia B.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Porcellati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2025.104233_bib1","first-page":"251","article-title":"The internal secretion of the pancreas","volume":"7","author":"Banting","year":"1922","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.numecd.2025.104233_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(18)85619-8","article-title":"Aqueous extracts of the pancreas. Influence on the carbohydrate metabolism of depancreatized animals","volume":"56","author":"Murlin","year":"1923","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2025.104233_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0021-9258(18)57183-0","article-title":"Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas","volume":"175","author":"Sutherland","year":"1948","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2025.104233_bib4","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1021\/ja01596a084","article-title":"The amino acid sequence of glucagon","volume":"78","author":"Bromer","year":"1956","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.numecd.2025.104233_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0021-9258(18)70910-1","article-title":"Purification and crystallization of glucagon","volume":"214","author":"Staub","year":"1955","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2025.104233_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/014107680009300313","article-title":"Insulin coma therapy in schizofrenia","volume":"93","author":"Kingsley","year":"2000","journal-title":"J R Sic Med"},{"key":"10.1016\/j.numecd.2025.104233_bib7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1172\/JCI104525","article-title":"Measurements of endogenous glucagon in plasma and the influence of blood glucose concentration upon its secretion","volume":"41","author":"Unger","year":"1962","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2025.104233_bib8","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0224","article-title":"Brief overview: glucagon history and physiology","volume":"258","author":"Robertson","year":"2023","journal-title":"J Endocrinol"},{"key":"10.1016\/j.numecd.2025.104233_bib9","first-page":"S28","article-title":"Glucagon: the effects of its excess and deficiency on insulin action","volume":"16","author":"Fanelli","year":"2006","journal-title":"NutrMetab Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.numecd.2025.104233_bib10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2337\/db15-1541","article-title":"Evidence of extrapancreatic glucagon secretion in man","volume":"65","author":"Lund","year":"2016","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.numecd.2025.104233_bib11","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2337\/diab.33.11.1112","article-title":"Glucose counterregulation in patients after pancreatectomy: comparison with other clinical forms of diabetes","volume":"33","author":"Polonsky","year":"1984","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104233_bib12","series-title":"Glucagon: molecular physiology, clinical and therapeutic implications","first-page":"61","article-title":"Glucagon-insulin interrelationships","author":"Samalos","year":"1972"},{"key":"10.1016\/j.numecd.2025.104233_bib13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1172\/JCI115375","article-title":"Intra-islet insulin permits glucose to directly suppress pancreatic A cell function","volume":"88","author":"Greenbaum","year":"1991","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2025.104233_bib14","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2337\/diabetes.53.6.1488","article-title":"Regulation of alpha cell function by beta cell in isolated human and rat islets deprived of glucose: the \u201cswitch-off\u201d hypothesis","volume":"53","author":"Hope","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104233_bib15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI112846","article-title":"Hyperglucagonemia and insulin-mediated glucose metabolism","volume":"79","author":"Del Prato","year":"1987","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2025.104233_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1172\/JCI107537","article-title":"Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men","volume":"53","author":"Liljenquist","year":"1974","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2025.104233_bib17","first-page":"E203","article-title":"Evidence against important catecholamine compensation for absent glucagon counterregulation","volume":"260","author":"De Feo","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.numecd.2025.104233_bib18","first-page":"333","article-title":"From physiology of glucose counterregulation to prevention of hypoglycaemia in type 1 diabetes mellitus","volume":"4","author":"Bolli","year":"1990","journal-title":"Diabetes NutrMetab"},{"key":"10.1016\/j.numecd.2025.104233_bib19","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/diab.42.11.1683","article-title":"Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM","volume":"42","author":"Fanelli","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104233_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1126\/science.182.4108.171","article-title":"Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha-cell defect","volume":"182","author":"Gerich","year":"1973","journal-title":"Science"},{"key":"10.1016\/j.numecd.2025.104233_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/diab.32.2.134","article-title":"Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion","volume":"32","author":"Bolli","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104233_bib22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2337\/diab.42.4.550","article-title":"Loss of potentiating effect of hypoglycemia on the glucagon response to hyperaminoacidemia in IDDM","volume":"42","author":"Caprio","year":"1993","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.numecd.2025.104233_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00125-006-0519-6","article-title":"Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemiceuglycaemia, hypoglycaemia and post-hypoglycaemichyperglycaemia","volume":"50","author":"Porcellati","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2025.104233_bib24","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.2337\/diabetes.52.11.2774","article-title":"Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans","volume":"52","author":"Porcellati","year":"2003","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.numecd.2025.104233_bib25","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2337\/db08-0276","article-title":"Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and Type 1 diabetic people","volume":"57","author":"Rossetti","year":"2008","journal-title":"Diabetes"},{"issue":"Suppl.1","key":"10.1016\/j.numecd.2025.104233_bib26","first-page":"S111","article-title":"Glycemic goals and hypoglycemia: standard of care in diabetes","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13300-016-0157-z","article-title":"Hypoglycemia event rates: a comparison between Real-World Data and Randomized Controlled Trial populations in insulin-treated diabetes","volume":"7","author":"Elliott","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2025.104233_bib28","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/edrv-12-4-356","article-title":"Hypoglycemiaun awareness","volume":"12","author":"Gerich","year":"1991","journal-title":"Endocr Rev"},{"key":"10.1016\/j.numecd.2025.104233_bib29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/dme.12496","article-title":"Hypoglycaemia symptoms and impaired awareness of hypoglycaemia in adults with Type 1 diabetes. The association with diabetes duration","volume":"31","author":"Olsen","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2025.104233_bib30","series-title":"American Diabetes Association: Alexandria, Egypt","first-page":"3","article-title":"Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. 3rd ed","author":"Cryer","year":"2016"},{"key":"10.1016\/j.numecd.2025.104233_bib31","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2337\/dc15-0533","article-title":"Seminal contributions to the understanding of hypoglycemia and glucose counterregulation and the discovery of HAAF (Cryer Syndrome)","volume":"38","author":"Dagogo-Jack","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib32","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1046\/j.1464-5491.2003.01072.x","article-title":"Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness","volume":"20","author":"Henderson","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.numecd.2025.104233_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2337\/dc11-0996","article-title":"The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study","volume":"35","author":"Seaquist","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib34","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3390\/biom11091281","article-title":"Glucagon as a therapeutic approach to severe hypoglycemia: after 100 years, is it still the antidote of insulin?","volume":"11","author":"Porcellati","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.numecd.2025.104233_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/dom.13941","article-title":"Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon","volume":"22","author":"Thieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2025.104233_bib36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/dia.2016.0460","article-title":"Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study","volume":"19","author":"Yale","year":"2017","journal-title":"Diabetes Tecnhol Ther"},{"issue":"4","key":"10.1016\/j.numecd.2025.104233_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2337\/dc15-1606","article-title":"Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with Type 1 diabetes","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02590783","article-title":"Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection","volume":"22","author":"Pontiroli","year":"1985","journal-title":"Acta Diabetol Lat"},{"issue":"3","key":"10.1016\/j.numecd.2025.104233_bib39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/dom.13134","article-title":"Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: a randomized clinical trial","volume":"20","author":"Guzman","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.numecd.2025.104233_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc15-1498","article-title":"Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study","volume":"39","author":"Rickels","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/dom.14019","article-title":"Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: a phase 3 randomized crossover study","volume":"22","author":"Matsuhisa","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2025.104233_bib42","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib43","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/dia.2019.0148","article-title":"Human factors usability and validation studies of glucagon autoinjector in a simulated severe hypoglycemia rescue situation","volume":"21","author":"Valentine","year":"2019","journal-title":"Diabetes Technol Therapeut"},{"issue":"12","key":"10.1016\/j.numecd.2025.104233_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00228-021-03183-0","article-title":"Dasiglucagon: an effective medicine for severe hypoglycemia","volume":"77","author":"Xu","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.numecd.2025.104233_bib45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/1932296818757795","article-title":"Stable liquid glucagon: beyond emergency hypoglycemia rescue","volume":"12","author":"Wilson","year":"2018","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.numecd.2025.104233_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11892-019-1216-4","article-title":"Novel preparations of glucagon for the prevention and treatment of hypoglycemia","volume":"19","author":"Hawkes","year":"2019","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.numecd.2025.104233_bib47","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/dc20-2106","article-title":"Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: an outpatient, randomized, crossover trial","volume":"44","author":"Blauw","year":"2021","journal-title":"Diabetes Care"},{"issue":"10067","key":"10.1016\/j.numecd.2025.104233_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(16)32567-3","article-title":"Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentrer andomised crossover trial","volume":"389","author":"El-Khatib","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.numecd.2025.104233_bib49","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.2337\/dc20-1086","article-title":"Performance of the insulin-only iLet bionic pancreas and the biohormonaliLet using Dasiglucagon in adults with type 1 diabetes in a home-use setting","volume":"44","author":"Castellanos","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pdi.1852","article-title":"Diabetic ketoacidosis in type 2 diabetes mellitus","volume":"31","author":"Puttanna","year":"2014","journal-title":"Pract Diabetes"},{"key":"10.1016\/j.numecd.2025.104233_bib51","article-title":"Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review","volume":"7","author":"FazeliFarsani","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.numecd.2025.104233_bib52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.numecd.2025.104233_bib53","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2025.104233_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in multicentric cohort","volume":"11","author":"Ata","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2025.104233_bib55","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2337\/dc19-2579","article-title":"Metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes","volume":"43","author":"Bolli","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib56","doi-asserted-by":"crossref","unstructured":"Kuhre RE, Ghiasi SM, Adriaenssens AE, Albrchtsen NJW, Andersen DB, Aivazidis A, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia 2019;62:1011\u20131023. https:\/\/doi.org\/10.1007\/s00125-019-4849-6.","DOI":"10.1007\/s00125-019-4849-6"},{"key":"10.1016\/j.numecd.2025.104233_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221130043","article-title":"Reallife evaluation of sodium- glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis","volume":"19","author":"Stougaard","year":"2022","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.numecd.2025.104233_bib58","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"issue":"00","key":"10.1016\/j.numecd.2025.104233_bib59","first-page":"1","article-title":"Combination SGLT2 inhibitor and glucagon receptor antagonist therapy in type1 diabetes: a randomized control trial","volume":"47","author":"Boeder","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.numecd.2025.104233_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2337\/dc23-0645","article-title":"Empagliflozin normalizes fasting hyperglycemia and improves postprandial glucose tolerance in totally pancreatectomized patients: a randomized, double-blind, placebo-controlled crossover study","volume":"47","author":"Baekdal","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2025.104233_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0026-0495(98)90185-8","article-title":"Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans","volume":"47","author":"Frank","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2025.104233_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00400639","article-title":"Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM","volume":"38","author":"Dinneen","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2025.104233_bib63","first-page":"4053","article-title":"Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus","volume":"85","author":"Shah","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2025.104233_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metabol"},{"issue":"Suppl 3","key":"10.1016\/j.numecd.2025.104233_bib65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2025.104233_bib66","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-007-0598-z","article-title":"Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects","volume":"50","author":"Meier","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2025.104233_bib67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Investig"},{"key":"10.1016\/j.numecd.2025.104233_bib68","doi-asserted-by":"crossref","first-page":"E418","DOI":"10.1210\/jc.2013-3644","article-title":"Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes","volume":"99","author":"Christensen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.numecd.2025.104233_bib69","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/db10-1332","article-title":"GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes","volume":"60","author":"Mentis","year":"2011","journal-title":"Diabetes"},{"issue":"10160","key":"10.1016\/j.numecd.2025.104233_bib70","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.numecd.2025.104233_bib71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2025.104233_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"issue":"16","key":"10.1016\/j.numecd.2025.104233_bib73","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3390\/ijms20163905","article-title":"Glucagon control on food intake and energy balance","volume":"20","author":"Al-Massadi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104233_bib74","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"Muller","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.numecd.2025.104233_bib75","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0149-7634(05)80042-9","article-title":"Pancreatic glucagon signals postprandial satiety","volume":"14","author":"Geary","year":"1990","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.numecd.2025.104233_bib76","first-page":"397","article-title":"Effect of intracerebroventricularly infused glucagon on feeding behaviour","volume":"33","author":"Inokuchi","year":"1984","journal-title":"Physiol Rev"},{"issue":"21","key":"10.1016\/j.numecd.2025.104233_bib77","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104233_bib78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(65)90761-0","article-title":"Promotion of insulin secretion by glucagon","volume":"286","author":"Samols","year":"1965","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.numecd.2025.104233_bib79","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/db19-0715","article-title":"Glucagon resistance ad the level of amino acid turnover in obese subjects with hepatic steatosis","volume":"69","author":"Suppli","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.numecd.2025.104233_bib80","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon receptor signaling and lipid metabolism","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.numecd.2025.104233_bib81","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int J Obes"},{"issue":"3","key":"10.1016\/j.numecd.2025.104233_bib82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lanced Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.numecd.2025.104233_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trials of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325003874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325003874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:58:43Z","timestamp":1763600323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325003874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0939475325003874"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104233","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new role for glucagon: from secondary hormone to key player","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104233"}}